immune insufficiency, hematologic malignancy, solid tumor
Conditions
Interventions
Intake period of Transmax resveratrol, 28 days
observation period, 15 days
control period, 42 days
Control period, 42 days
intake period of Transmax resveratrol, 28 days
Intake period of Melinjo resveratrol, 28 days
intake period of Melinjo resveratrol, 28 days
Sponsors
Kanazawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: No subjective symptom, drinking three times or less a week, and normal liver and renal function that has been confirmed in a medical examination within one year.
Exclusion criteria
Exclusion criteria: Any of the following: currently receiving a drug therapy, currently having chronic diseases such as heart, lung, kidney, gastrointestinal, and inflammatory diseases, suffering from invasive cancer within five years, suffering from non-invasive cancer within a year, and a history of smoking within one year.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Influence of resveratrol in the expression of NK related receptors on NK cells. Influence of resveratrol in the NK cell activity. | — |
Primary
| Measure | Time frame |
|---|---|
| Resveratrol related toxicity during 12 weeks after the start of oral administration of resveratrol | — |
Countries
Japan
Contacts
Public ContactAkiyoshi Takami
Kanazawa University Hospital Division of Transfusion Medicine and Department of Hematology and Oncology
Outcome results
None listed